EGFR mutation positivity was associated with longer OS, suggesting that the prognosis of EGFR mutation‐related lung cancer could be improved by EGFR‐targeted therapy, which may also apply to incidences of resected NSCLC. The gene discussed is EGFR; the disease is lung cancer.